Could IMMUNOCELLULAR THERAPEUTICS LTD (OTCMKTS:IMUC) Go Up After Its Newest Short Interest Report?

ImmunoCellular Therapeutics, Ltd. (OTCMKTS:IMUC) Logo

The stock of IMMUNOCELLULAR THERAPEUTICS LTD (OTCMKTS:IMUC) registered an increase of 33.33% in short interest. IMUC’s total short interest was 1,200 shares in September as published by FINRA. Its up 33.33% from 900 shares, reported previously.

The stock decreased 13.61% or $0.0046 during the last trading session, reaching $0.029. About 8,185 shares traded. ImmunoCellular Therapeutics, Ltd. (OTCMKTS:IMUC) has declined 89.43% since September 13, 2018 and is downtrending. It has underperformed by 89.43% the S&P500.

ImmunoCellular Therapeutics, Ltd., a clinical-stage biotechnology company, develops immune therapies for the treatment of various cancers. The company has market cap of $1.22 million. The Company’s lead product candidate is ICT-107, a dendritic cell immunotherapy targeting cancer stem cells (CSCs) and cancer antigens, which is in Phase III clinical trials for the treatment of glioblastoma multiforme (GBM). It currently has negative earnings. The firm is also developing ICT-140, a DC immunotherapy targeting CSCs and cancer antigens that is in Phase I clinical trials for the treatment of ovarian cancer; and ICT-121, a DC immunotherapy targeting CD133 markers and CSCs, which is in Phase I clinical trials to treat recurrent GBM and other solid tumor cancers.

More notable recent ImmunoCellular Therapeutics, Ltd. (OTCMKTS:IMUC) news were published by: Seekingalpha.com which released: “The Long And Short Cases For Telik – Seeking Alpha” on January 16, 2013, also Seekingalpha.com with their article: “Northwest Bio And The Curious Relationship With Cognate BioServices – Seeking Alpha” published on July 17, 2014, Seekingalpha.com published: “ImmunoCellular advances Stem-to-T-Cell technology; shares up 27% premarket – Seeking Alpha” on April 12, 2018. More interesting news about ImmunoCellular Therapeutics, Ltd. (OTCMKTS:IMUC) were released by: Seekingalpha.com and their article: “ImmunoCellular’s ICT-107 Phase II: Patience Will Pay Off – Seeking Alpha” published on December 11, 2013 as well as Businesswire.com‘s news article titled: “HemaCare Reports Full Year 2018 Results – Business Wire” with publication date: March 26, 2019.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.